Wyeth Reports Earnings Results for the 2007 Fourth Quarter and... (2007 but is now subject to genericcompet...)

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

Date:1/31/2008

2007, but is now subject to generic competition. On January 29, 2008, Wyeth and its business partner, Nycomed, announced the U.S. launch of Wyeth's own generic version of Protonix tablets, following the at-risk launch of generic pantoprazole tablets in the United States by Teva Pharmaceuticals USA, Inc. (Teva) on December 21, 2007. In addition, Sun Pharmaceutical Industries Ltd. (Sun) announced its launch of generic pantoprazole tablets in the United States on January 30, 2008. Wyeth intends to continue its litigation against both Teva and Sun to enforce the Protonix patent.

Additional information regarding Wyeth's product sales may be accessed on the Company's Internet Web site at http://www.wyeth.com by clicking on the "Investor Relations" hyperlink.

R&D Update

In October 2007, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's supplemental New Drug Application for its first-in-class antibiotic TYGACIL (tigecycline) for the treatment of patients with community- acquired pneumonia. In November 2007, the European Commission approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma. Torisel was approved in the United States in May 2007 for the same indication. In December 2007, Wyeth received a second approvable letter from the FDA for VIVIANT(TM) (bazedoxifene), a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis. The FDA has now advised the Company that the agency expects to convene an Advisory Committee meeting in July to review both the treatment and prevention of osteoporosis indications for Viviant. In addition, in December, Wyeth and its partner Elan Corporation announced the initiation of patient dosing in a global Phase 3 clinical program for bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease. On January 10, 2008, Wyeth and its business partner Proge
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and...(2007 but is now subject to genericcompet...)